Cargando…

Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity

BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivodic, Aldina, Johansson, Helena, Smith, Lois E H, Hård, Anna-Lena, Löfqvist, Chatarina, Yoder, Bradley A, Hartnett, M Elizabeth, Wu, Carolyn, Bründer, Marie-Christine, Lagrèze, Wolf A, Stahl, Andreas, Al-Hawasi, Abbas, Larsson, Eva, Lundgren, Pia, Gränse, Lotta, Sunnqvist, Birgitta, Tornqvist, Kristina, Wallin, Agneta, Holmström, Gerd, Albertsson-Wikland, Kerstin, Nilsson, Staffan, Hellström, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627649/
https://www.ncbi.nlm.nih.gov/pubmed/33980506
http://dx.doi.org/10.1136/bjophthalmol-2020-318719
_version_ 1784606876111994880
author Pivodic, Aldina
Johansson, Helena
Smith, Lois E H
Hård, Anna-Lena
Löfqvist, Chatarina
Yoder, Bradley A
Hartnett, M Elizabeth
Wu, Carolyn
Bründer, Marie-Christine
Lagrèze, Wolf A
Stahl, Andreas
Al-Hawasi, Abbas
Larsson, Eva
Lundgren, Pia
Gränse, Lotta
Sunnqvist, Birgitta
Tornqvist, Kristina
Wallin, Agneta
Holmström, Gerd
Albertsson-Wikland, Kerstin
Nilsson, Staffan
Hellström, Ann
author_facet Pivodic, Aldina
Johansson, Helena
Smith, Lois E H
Hård, Anna-Lena
Löfqvist, Chatarina
Yoder, Bradley A
Hartnett, M Elizabeth
Wu, Carolyn
Bründer, Marie-Christine
Lagrèze, Wolf A
Stahl, Andreas
Al-Hawasi, Abbas
Larsson, Eva
Lundgren, Pia
Gränse, Lotta
Sunnqvist, Birgitta
Tornqvist, Kristina
Wallin, Agneta
Holmström, Gerd
Albertsson-Wikland, Kerstin
Nilsson, Staffan
Hellström, Ann
author_sort Pivodic, Aldina
collection PubMed
description BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to safely reduce screening of those infants not needing treatment. DIGIROP-Screen was compared with four other ROP models based on longitudinal weights. METHODS: Data, including infants born at 24–30 weeks of gestational age (GA), for DIGIROP-Screen development (DevGroup, N=6991) originate from the Swedish National Registry for ROP. Three international cohorts comprised the external validation groups (ValGroups, N=1241). Multivariable logistic regressions, over postnatal ages (PNAs) 6–14 weeks, were validated. Predictors were birth characteristics, status and age at first diagnosed ROP and essential interactions. RESULTS: ROP treatment was required in 287 (4.1%)/6991 infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To allow 100% sensitivity in DevGroup, specificity at birth was 53.1% and cumulatively 60.5% at PNA 8 weeks. Applying the same cut-offs in ValGroups, specificities were similar (46.3% and 53.5%). One infant with severe malformations in ValGroups was incorrectly classified as not needing screening. For all other infants, at PNA 6–14 weeks, sensitivity was 100%. In other published models, sensitivity ranged from 88.5% to 100% and specificity ranged from 9.6% to 45.2%. CONCLUSIONS: DIGIROP-Screen, a clinical decision support tool using readily available birth and ROP screening data for infants born GA 24–30 weeks, in the European and North American populations tested can safely identify infants not needing ROP screening. DIGIROP-Screen had equal or higher sensitivity and specificity compared with other models. DIGIROP-Screen should be tested in any new cohort for validation and if not validated it can be modified using the same statistical approaches applied to a specific clinical setting.
format Online
Article
Text
id pubmed-8627649
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86276492022-10-28 Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity Pivodic, Aldina Johansson, Helena Smith, Lois E H Hård, Anna-Lena Löfqvist, Chatarina Yoder, Bradley A Hartnett, M Elizabeth Wu, Carolyn Bründer, Marie-Christine Lagrèze, Wolf A Stahl, Andreas Al-Hawasi, Abbas Larsson, Eva Lundgren, Pia Gränse, Lotta Sunnqvist, Birgitta Tornqvist, Kristina Wallin, Agneta Holmström, Gerd Albertsson-Wikland, Kerstin Nilsson, Staffan Hellström, Ann Br J Ophthalmol Clinical Science BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to safely reduce screening of those infants not needing treatment. DIGIROP-Screen was compared with four other ROP models based on longitudinal weights. METHODS: Data, including infants born at 24–30 weeks of gestational age (GA), for DIGIROP-Screen development (DevGroup, N=6991) originate from the Swedish National Registry for ROP. Three international cohorts comprised the external validation groups (ValGroups, N=1241). Multivariable logistic regressions, over postnatal ages (PNAs) 6–14 weeks, were validated. Predictors were birth characteristics, status and age at first diagnosed ROP and essential interactions. RESULTS: ROP treatment was required in 287 (4.1%)/6991 infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To allow 100% sensitivity in DevGroup, specificity at birth was 53.1% and cumulatively 60.5% at PNA 8 weeks. Applying the same cut-offs in ValGroups, specificities were similar (46.3% and 53.5%). One infant with severe malformations in ValGroups was incorrectly classified as not needing screening. For all other infants, at PNA 6–14 weeks, sensitivity was 100%. In other published models, sensitivity ranged from 88.5% to 100% and specificity ranged from 9.6% to 45.2%. CONCLUSIONS: DIGIROP-Screen, a clinical decision support tool using readily available birth and ROP screening data for infants born GA 24–30 weeks, in the European and North American populations tested can safely identify infants not needing ROP screening. DIGIROP-Screen had equal or higher sensitivity and specificity compared with other models. DIGIROP-Screen should be tested in any new cohort for validation and if not validated it can be modified using the same statistical approaches applied to a specific clinical setting. BMJ Publishing Group 2022-11 2021-05-12 /pmc/articles/PMC8627649/ /pubmed/33980506 http://dx.doi.org/10.1136/bjophthalmol-2020-318719 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Clinical Science
Pivodic, Aldina
Johansson, Helena
Smith, Lois E H
Hård, Anna-Lena
Löfqvist, Chatarina
Yoder, Bradley A
Hartnett, M Elizabeth
Wu, Carolyn
Bründer, Marie-Christine
Lagrèze, Wolf A
Stahl, Andreas
Al-Hawasi, Abbas
Larsson, Eva
Lundgren, Pia
Gränse, Lotta
Sunnqvist, Birgitta
Tornqvist, Kristina
Wallin, Agneta
Holmström, Gerd
Albertsson-Wikland, Kerstin
Nilsson, Staffan
Hellström, Ann
Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title_full Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title_fullStr Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title_full_unstemmed Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title_short Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
title_sort development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627649/
https://www.ncbi.nlm.nih.gov/pubmed/33980506
http://dx.doi.org/10.1136/bjophthalmol-2020-318719
work_keys_str_mv AT pivodicaldina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT johanssonhelena developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT smithloiseh developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT hardannalena developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT lofqvistchatarina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT yoderbradleya developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT hartnettmelizabeth developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT wucarolyn developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT brundermariechristine developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT lagrezewolfa developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT stahlandreas developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT alhawasiabbas developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT larssoneva developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT lundgrenpia developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT granselotta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT sunnqvistbirgitta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT tornqvistkristina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT wallinagneta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT holmstromgerd developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT albertssonwiklandkerstin developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT nilssonstaffan developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity
AT hellstromann developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity